This morning Champignon Brands Inc. (CSE: SHRM) announced the appointment of Pat McCutcheon to its board of directors effective immediately. McCutcheon is currently CEO of MediPharm Labs (TSX: LABS), one of the most respected cannabis operations in Canada. And notably one of the few cash flow generating operators. He founded MediPharm after identifying an important, overlooked segment of the burgeoning cannabis market to create the first pure-play cannabis company focused solely on extraction and API manufacturing.
Prior to founding MediPharm, McCutcheon held senior roles with various large pharmaceutical companies – including Jansen Pharmaceuticals (Johnson & Johnson), Sanofi and Astra Zeneca. During his tenure at Jansen, he was head of the hospital division for renal and mental health products.
Champignon Brands closed yesterday at $1.06, up 381% since first trading March 2, 2020.
FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
SmallCapSteve started blogging in the Winter of 2009. During that time, he was able to spot many take over candidates and pick a variety of stocks that generated returns in excess of 200%. Today he consults with microcap companies helping them with capital markets strategy and focuses on industries including cannabis, tech, and junior mining.
The post Champignon Brands Appoints Medipharm Labs CEO Pat McCutcheon to Board appeared first on the deep dive.